SI-BONE, Inc. Announces Additional Exclusive Coverage Policies for iFuse
February 04 2019 - 8:00AM
SI-BONE, Inc. (Nasdaq: SIBN), a medical device company that
pioneered minimally invasive surgery of the sacroiliac (SI) joint
with the iFuse Implant System® (iFuse) announced the addition of
several exclusive coverage policies.
“We are pleased with the growing body of commercial health
care plans offering exclusive reimbursement policies for the iFuse
Implant System,” said Jeffrey Dunn, President, Chief Executive
Officer, and Chairman. “We continue to make progress expanding our
market leadership in providing minimally invasive surgical products
for the sacroiliac joint and improving patient lives.”
CareFirst BlueCross BlueShield, Premera Blue Cross Blue
Shield and Excellus BlueCross BlueShield have published positive
coverage policies for MIS SI joint fusion when performed
exclusively with the triangular iFuse Implant System (iFuse)
providing coverage for over 6.5 million lives. In total,
there are 32 Blue Cross Blue Shield plans that now cover MIS SI
joint fusion, 27 of which are exclusive to the triangular iFuse
Implant System based on published clinical evidence.
- CareFirst is the largest health care insurer in the
Mid-Atlantic region, covering 3.2 million members in Maryland, the
District of Columbia and parts of Northern Virginia. CareFirst’s
iFuse only policy took effect January 1, 2019.
- Premera Blue Cross is the largest health plan in the Pacific
Northwest, covering over 2 million lives throughout Washington and
Alaska. The Premera exclusive iFuse policy became effective
February 1, 2019.
- Excellus BlueCross BlueShield policy took effect December 20,
2018 and provides access to the iFuse Procedure for almost 1.5
million customers in central and upstate New York.
All three of these recent positive and exclusive coverage
policies for iFuse were based on review of published clinical
evidence and conclude that published results from two randomized
controlled trials of iFuse versus conservative care, in addition to
several cohort studies and numerous case series, demonstrate that
evidence is sufficient to determine the effect on health outcomes
and therefore treatment of SI joint dysfunction with triangular
titanium implants may be considered medically necessary for
appropriately diagnosed patients.
About SI-BONESI-BONE is a medical device
company that pioneered the iFuse Implant System, a minimally
invasive surgical system for fusion of the sacroiliac joint to
treat sacroiliac joint dysfunction. The SI joint is believed
to be the last major joint with a clinically proven surgical
treatment. The iFuse Implant, commercially available since
2009, is believed to be the only SI joint fusion device
supported by multiple prospective clinical studies showing improved
pain, patient function and quality of life resulting from
treatment. There are over 60 peer-reviewed publications
supporting the safety, effectiveness, and biomechanical and
economic benefits unique to the iFuse Implant
(www.si-bone.com/results). This body of evidence has enabled
multiple government and private insurance payors to establish
coverage of the SI joint fusion procedure exclusively when
performed with the iFuse Implant System.
The iFuse Implant System is intended for sacroiliac fusion for
conditions including sacroiliac joint dysfunction that is a direct
result of sacroiliac joint disruption and degenerative
sacroiliitis. This includes conditions whose symptoms began
during pregnancy or in the peripartum period and have persisted
postpartum for more than 6 months. There are potential risks
associated with the iFuse Implant System. It may not be
appropriate for all patients and all patients may not
benefit.
SI-BONE and iFuse Implant System are registered trademarks of
SI-BONE, Inc. ©2019 SI-BONE, Inc. All Rights Reserved.
10310.020419
Media Contact:Joe Powers, Vice President of
Marketingjpowers@si-bone.com
Investor Contact:Lynn Lewis or Carrie
Mendivilinvestors@SI-BONE.com
SI BONE (NASDAQ:SIBN)
Historical Stock Chart
From Jun 2024 to Jul 2024
SI BONE (NASDAQ:SIBN)
Historical Stock Chart
From Jul 2023 to Jul 2024